The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer
Open accessAbstract
Netrin-1 is upregulated in cancers as a protumoural mechanism 1. Here we describe netrin-1 upregulation in a majority of human endometrial carcinomas (ECs) and demonstrate that netrin-1 blockade, using an anti-netrin-1 antibody (NP137), is effective in reduction of tumour progression in an EC mouse model. We next examined the efficacy of NP137, as a first-in-class single agent, in a Phase I trial comprising 14 patients with advanced EC. As best response we observed 8 stable disease (8 out of 14, 57.1%) and 1 objective response as RECIST v.1.1 (partial response, 1 out of 14 (7.1%), 51.16% reduction in target lesions at 6 weeks and up to 54.65% reduction during the following 6 months). To evaluate the NP137 mechanism of action, mouse tumour gene profiling was performed, and we observed, in addition to cell death induction, that NP137 inhibited epithelial-to-mesenchymal transition (EMT). By performing bulk RNA sequencing (RNA-seq), spatial transcriptomics and single-cell RNA-seq on paired pre- and on-treatment biopsies from patients with EC from the NP137 trial, we noted a net reduction in tumour EMT. This was associated with changes in immune infiltrate and increased interactions between cancer cells and the tumour microenvironment. Given the importance of EMT in resistance to current standards of care 2, we show in the EC mouse model that a combination of NP137 with carboplatin-paclitaxel outperformed carboplatin-paclitaxel alone. Our results identify netrin-1 blockade as a clinical strategy triggering both tumour debulking and EMT inhibition, thus potentially alleviating resistance to standard treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
Fitamant, J., Guenebeaud, C., Coissieux, M.-M., Guix, C., Treilleux, I., Scoazec, J.-Y., Bachelot, T., Bernet, A., & Mehlen, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709810105 · Cited by 241
Self-citationStructural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers
Grandin, M., Meier, M., Delcros, J. G., Nikodemus, D., Reuten, R., Patel, T. R., Goldschneider, D., Orriss, G., Krahn, N., Boussouar, A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.001 · Cited by 128
Self-citationDependence Receptors and Cancer: Addiction to Trophic Ligands
Gibert, B., & Mehlen, P. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3652 · Cited by 73
Self-citation
Research works printed but not linked: 23
- Mehlen, P., Delloye-Bourgeois, C. & Chédotal, A. Novel roles for Slits and netrins: axon guidance cues as anticancer targets? Nat. Rev. Cancer 11, 188–197 (2011). · DOI · Paper page
- Brisset, M., Grandin, M., Bernet, A., Mehlen, P. & Hollande, F. Dependence receptors: new targets for cancer therapy. EMBO Mol. Med. 13, e14495 (2021). · DOI
- Wu, Z. et al. Long-range guidance of spinal commissural axons by netrin1 and sonic hedgehog from midline floor plate cells. Neuron 101, 635–647 (2019). · DOI
- Sung, P.-J. et al. Cancer-associated fibroblasts produce netrin-1 to control cancer cell plasticity. Cancer Res. 79, 3651–3661 (2019). · DOI
- Paradisi, A. et al. NF-κB regulates netrin-1 expression and affects the conditional tumor suppressive activity of the netrin-1 receptors. Gastroenterology 135, 1248–1257 (2008). · DOI
- Paradisi, A. et al. Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression. Proc. Natl Acad. Sci. USA 106, 17146–17151 (2009). · DOI
- Delloye-Bourgeois, C. et al. Interference with netrin-1 and tumor cell death in non-small cell lung cancer. J. Natl Cancer Inst. 101, 237–247 (2009). · DOI
- Delloye-Bourgeois, C. et al. Netrin-1 acts as a survival factor for aggressive neuroblastoma. J. Exp. Med. 206, 833–847 (2009). · DOI
- Broutier, L. et al. Targeting netrin‐1/ DCC interaction in diffuse large B‐cell and mantle cell lymphomas. EMBO Mol. Med. 8, 96–104 (2016). · DOI
- Boussouar, A. et al. Netrin-1 and its receptor DCC are causally implicated in melanoma progression. Cancer Res. 80, 747–756 (2020). · DOI
- Cassier, P. et al. A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. Ann. Oncol. 30, v159 (2019). · doi:10.1093/annonc/mdz244.001
- Mirantes, C. et al. An inducible knock-out mouse to model cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias. Dis. Model. Mech6, 710–720 (2013). · DOI
- Yan, W. et al. Netrin-1 induces epithelial–mesenchymal transition and promotes hepatocellular carcinoma invasiveness. Dig. Dis. Sci. 59, 1213–1221 (2014). · DOI
- Jin, X. et al. Netrin-1 interference potentiates epithelial-to-mesenchymal transition through the PI3K/AKT pathway under the hypoxic microenvironment conditions of non-small cell lung cancer. Int. J. Oncol. 54, 1457–1465 (2019). · DOI
- Zhang, X. et al. Netrin-1 elicits metastatic potential of non-small cell lung carcinoma cell by enhancing cell invasion, migration and vasculogenic mimicry via EMT induction. Cancer Gene Ther. 25, 18–26 (2018). · doi:10.1038/s41417-017-0008-8
- Chen, Y. et al. Bradykinin promotes migration and invasion of hepatocellular carcinoma cells through TRPM7 and MMP2. Exp. Cell. Res. 349, 68–76 (2016). · DOI
- Mak, M. P. et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin. Cancer Res. 22, 609–620 (2016). · DOI · Paper page
- Bignotti, E. et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br. J. Cancer 104, 1418–1425 (2011). · doi:10.1038/bjc.2011.109
- DeConti, R. C. Chemotherapy of squamous cell carcinoma of the skin. Semin. Oncol. 39, 145–149 (2012). · doi:10.1053/j.seminoncol.2012.01.002
- Paradisi, A. et al. Combining chemotherapeutic agents and netrin‐1 interference potentiates cancer cell death. EMBO Mol. Med. 5, 1821–1834 (2013). · DOI
- Lambert, A. W. & Weinberg, R. A. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat. Rev. Cancer 21, 325–338 (2021). · DOI · Paper page
- Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018). · DOI · Paper page
- Brabletz, S., Schuhwerk, H., Brabletz, T. & Stemmler, M. P. Dynamic EMT: a multi‐tool for tumor progression. EMBO J. 40, e108647 (2021). · DOI · Paper page
Cited by
Wnt/β-catenin-driven EMT regulation in human cancers
Xue, W., Yang, L., Chen, C., Ashrafizadeh, M., Tian, Y., & Sun, R. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05099-7 · Cited by 321
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“Exploring the therapeutic implications of emerging surface targets associated with the EMT phenotype, including Netrin-1 (67, 68) and CD70 (69), may prove promising in combination with KRAS inhibition.”
Background
Metadata
- Authors
- Cassier, P. A., Navaridas, R., Bellina, M., Rama, N., Ducarouge, B., Hernandez-Vargas, H., Delord, J.-P., Lengrand, J., Paradisi, A., Fattet, L., Garin, G., Gheit, H., Dalban, C., Pastushenko, I., Neves, D., Jelin, R., Gadot, N., Braissand, N., Léon, S., Degletagne, C., Matias-Guiu, X., Devouassoux-Shisheboran, M., Mery-Lamarche, E., Allard, J., Zindy, E., Decaestecker, C., Salmon, I., Perol, D., Dolcet, X., Ray-Coquard, I., Blanpain, C., Bernet, A., & Mehlen, P.
- Venue
- Nature
- Published
- 2023-08-02
- Volume
- 620
- Issue
- 7973
- Pages
- 409-416
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4385490576
- Cited by
- 161
- References
- 5
- FWCI
- 44.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. https://app.cochat.ai/papers/10.1038/s41586-023-06367-z
- The paper
- Cassier, P. A., Navaridas, R., Bellina, M., Rama, N., Ducarouge, B., Hernandez-Vargas, H., Delord, J.-P., Lengrand, J., Paradisi, A., Fattet, L., Garin, G., Gheit, H., Dalban, C., Pastushenko, I., Neves, D., Jelin, R., Gadot, N., Braissand, N., Léon, S., . . . Mehlen, P. (2023). Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature. https://doi.org/10.1038/s41586-023-06367-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.